Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257983 | 0.81 | GRM5 (0.54) | GRM5MAOBRAB9AALDH1A1NPC1 | |
| SCHEMBL7683241 | 0.77 | TSHR (0.58) | MAOBCYP2C19ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL7689298 | 0.73 | HPGD (0.52) | CYP2C19ALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL12983650 | 0.73 | CYP2C19 (0.58) | GRM5CYP2C19RAB9AALDH1A1NPC1 | |
| SCHEMBL9909843 | 0.73 | HTR2A (0.38) | GRM5MAOBCYP2C19RAB9AALDH1A1 | |
| SCHEMBL31067757 | 0.73 | CYP2C19 (0.58) | GRM5CYP2C19RAB9AALDH1A1NPC1 | |
| SCHEMBL9835747 | 0.71 | GRM5 (0.51) | GRM5MAOBRAB9AALDH1A1NPC1 | |
| SCHEMBL4174505 | 0.71 | CYP2C19 (0.41) | GRM5MAOBCYP2C19 | |
| SCHEMBL9953953 | 0.71 | GRM5 (1.00) | GRM5MAOBRAB9AALDH1A1NPC1 | |
| SCHEMBL3894956 | 0.70 | CYP2C19 (0.54) | GRM5MAOBCYP2C19RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-4603199-A | Phenyl-substituted tricyclic antibacterial agent intermediates | RIKER LABORATORIES, INC. (US) | 1986-07-29 | — | — | US | disclosed |
| US-4443447-A | Phenyl-substituted tricyclic antibacterial agents | RIKER LABORATORIES, INC. (US) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | GRM5 480/4885MAOB 19/4885CYP2C19 40/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | GRM5 635/4885MAOB 46/4885CYP2C19 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.